Recent Finacing
Recent Raise
Prolium Bioscience is a NYC-based clinical-stage biotech developing a bispecific CD20xCD3 antibody therapy for systemic sclerosis and other severe autoimmune diseases.
Focus Areas
Recent Investors
Total Raised
Funding round
